We guarantee to make you the best humanized antibody

We have been delivering humanized antibodies since 1987 and our expertise is used by the world’s leading pharmaceutical and biotech companies.

The antibody humanization technique we use (CDR grafting) was developed at the MRC giving our scientists unrivalled knowledge about this specialised discipline.

Our antibody engineering expertise has helped to put humanized antibody drugs on the market, including Keytruda®, Tysabri® and Actemra®.

  • No antibody - no invoice!

    Unlike our competitors we continue to applying our proven experience until we reach the optimum humanized antibody candidate. What’s more, we believe in payment by results; we will deliver the best candidate and you don’t have to risk wasting time or money.


    We don’t ask for upfront payments but instead have a shared risk model. Please contact us for more details.

  • Adding value

    We offer biophysical characterisation as routine and on collaboration projects we offer other engineering services such as affinity maturation.

  • Our track record

    We have humanized more than 58 antibodies.

    Our development work has already delivered four marketed drugs: Keytruda®  (pembrolizumab /MK-3475), Tysabri®, Actemra® and Entyvio®.

    A further five are in clinical trials with another two in preclinical studies.

  • AERES Biomedical

    (Please note that AERES Biomedical, a subsidiary of MRC Technology, has  ceased trading. MRC Technology now handles all antibody humanization services directly).